<DOC>
	<DOCNO>NCT02288741</DOCNO>
	<brief_summary>Patients 60 70 year age newly diagnose multiple myeloma prospectively randomize 4 cycle anthracycline/dexamethasone-based induction chemotherapy ( A1 ) 2 x 4 day dexamethasone ( A2 ) . A reference arm include patient could randomize ( B ) . Tandem melphalan 140 mg/m² ( MEL140 ) autologous transplantation schedule patient .</brief_summary>
	<brief_title>Tandem Melphalan Autolog . SCT MM Patients 60 70 Years Age With Without Induction Chemotherapy</brief_title>
	<detailed_description>In arm A1 , patient receive 4 cycle conventional induction therapy anthracycline/dexamethasone-based regimen . Specified protocol vincristine/doxorubicin/dexamethasone ( VAD ) , idarubicin/dexamethasone ( ID ) cyclophosphamide/doxorubicin/dexamethasone ( CAD ) . In arm A2 , patient plan receive dexamethasone 40 mg orally day 1-4 8-11 symptom control stem cell mobilization . For patient arm B , maximum 6 cycle induction chemotherapy allow . Following , treatment identical patient . For stem cell mobilization , age-adjusted IEV-regimen granulocyte-colony stimulating factor ( G-CSF ) recommend . The target dose stem cell collection 6 x 10E+6 CD34 ( cluster differentiation 34 ) -positive cells/kg ( 2 transplant one back-up ) . The standard dose transplantation 2 x 10E+6 CD34-positive cells/kg . High-dose melphalan total dose 140 mg/m² ( MEL140 ) give two dos 70 mg/m² day -3 -2 . Stem cell transplantation ( SCT ) perform day 0 . A second MEL140 course plan two month first . Regular bisphosphonate treatment recommend .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Histological confirm multiple myeloma stage II III accord classification Salmon Durie Aged 60 70 year Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Signed date write informed consent No previous chemotherapy one cycle total previous chemotherapy one cycle pause least 6 month six cycle total ( arm A1 A2 ) Ongoing primary chemotherapy two maximum six cycle ( arm B ) Multiple myeloma stage I accord classification Salmon Durie without need therapy Aged 60 70 year ECOG performance status &gt; 2 Previous chemotherapy six cycle Informed consent miss Myocardial infarction within last six month Cardiac dysrhythmia stage IV b accord classification Lown Heart failure &gt; NYHA II accord classification New York Heart Association ( NYHA ) , leave ventricular ejection fraction &lt; 50 % ECG Severe restrictive obstructive pulmonary disease ( diffuse capacity &lt; 60 % normal ) Renal insufficiency include serum creatinine level &gt; 2mg/dl caused multiple myeloma reversible Liver disease combine elevation transaminase bilirubin three time normal Severe infection ( HIV , hepatitis B/C , syphilis etc . ) Severe psychiatric disease Other curative treat malignant tumor within last five year Concurrent participation clinical study Other curative treat malignant tumor within last five year</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>high-dose chemotherapy</keyword>
	<keyword>autologous blood stem-cell transplantation</keyword>
	<keyword>induction chemotherapy</keyword>
	<keyword>elderly patient</keyword>
</DOC>